Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8227484 | AVANIR PHARMS | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
Jul, 2023
(3 months from now) | |
US7659282 | AVANIR PHARMS | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
Aug, 2026
(3 years from now) |
Drugs and Companies using DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE ingredient
Market Authorisation Date: 29 October, 2010
Treatment: Treatment of pseudobulbar affect
Dosage: CAPSULE;ORAL
16
United States
12
Japan
9
Australia
7
Korea, Republic of
6
European Union
5
Israel
2
Portugal
2
Spain
2
Norway
2
Hong Kong
2
Slovenia
2
Hungary
2
Poland
2
Denmark
1
Germany
1
Russia
1
Austria
1
Taiwan, Province of China
1
Belgium
1
Canada
1
Cyprus
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic